ME Therapeutics Holdings Inc

PreveCeutical Medical Inc is a Vancouver-based company dedicated to developing innovative options for preventive and curative therapies, leveraging both nature and science to benefit health-conscious consumers. Through collaboration with its partners, the company focuses on researching and creating solutions that provide consumers with effective health options. With a vested interest in the preventive health sector, PreveCeutical is actively engaged in various programs, including cannabinoid delivery systems and non-addictive analgesics, aimed at addressing significant health challenges. The company's commitment to innovation positions it as a key player in the evolving landscape of health and wellness solutions. Generated from the website

Delic Holdings Corp, based in Vancouver, BC, is a leader in the development and accessibility of psychedelic-based treatments, boasting the largest profitable network of clinics in the U.S. The company focuses on long-term solutions that address the root causes of mental health issues, offering effective alternatives to traditional medicines with minimal side effects. Recognizing the growing mental health crisis affecting billions globally, Delic Holdings aims to provide personalized and reliable treatment options that foster emotional wellness. Their integrated approach not only educates the public on psychedelics but also initiates important conversations about mental health management. Generated from the website

Algernon Pharmaceuticals Inc., based in Vancouver, BC, is a clinical-stage Canadian drug development and repurposing company focused on addressing unmet global medical needs through innovative therapeutic applications. The company employs a cost-effective drug repurposing model, leveraging existing compounds with established safety profiles to expedite the discovery of new treatments for various diseases. Algernon's current pipeline includes NP251 (Repirinast), originally developed for asthma, now being repurposed for chronic kidney disease, and AP188 (NN-Dimethyltryptamine), which is being investigated as a potential treatment for stroke and traumatic brain injury. The company is also advancing its research through its subsidiary, Algernon NeuroScience, and is actively conducting clinical trials to support its drug development programs. Generated from the website